|Bid||64.05 x 800|
|Ask||64.11 x 800|
|Day's Range||63.30 - 64.49|
|52 Week Range||56.56 - 85.97|
|Beta (5Y Monthly)||0.42|
|PE Ratio (TTM)||654.17|
|Earnings Date||Apr 28, 2021 - May 03, 2021|
|Forward Dividend & Yield||2.84 (4.49%)|
|Ex-Dividend Date||Mar 12, 2021|
|1y Target Est||74.54|
Yahoo Finance’s Julie Hyman, Myles Udland and Brian Sozzi discuss how vaccines are having a major impact on airlines.
The National Institutes of Health said Thursday that it is putting three more investigational COVID-19 treatments into Phase 2/3 clinical trials. The experimental therapies are: an inhalable beta interferon developed by Synairgen's ; AstraZeneca's monoclonal antibody combination, which will be tested as an infusion and also as an injection; and Sagent Pharmaceuticals Inc.'s oral serine protease inhibitor. Sagent is privately held. The NIH said it is trying to identify and study therapies aimed at treating people who develop mild or moderate forms of COVID-19. So far during the pandemic, there are few therapies available that effectively treat patients with COVID-19. Only one, Gilead Sciences Inc.'s Veklury, has received full approval from the Food and Drug Administration, though several other companies, including Eli Lilly & Co. and Regeneron Pharmaceuticals Inc. have received emergency authorization for their antibody treatments. Over the past year, Synairgen's stock has soared 763.1%, while U.S.-listed shares of AstraZeneca are up 0.4%. The broader S&P 500 is up 27.2%.
The U.S. death toll from the coronavirus-borne illness COVID-19 climbed above 518,000 on Thursday, as President Joe Biden added his voice to a chorus of outrage over Texas and Mississippi's decision to reopen their states for business, just as declining case numbers are stalling and public health experts are urging Americans to stick with safety measures.